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Prophylactic intracavitary treatment with interferon
alpha increases interferon gamma production by
peripheral blood mononuclear cells in patients with
superficial transitional cell carcinoma of the bladder
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Summary The immunomodulatory effect of prophylactic intravesical instillations of interferon alpha 2b (IFN-a-2b) on interferon gamma
(IFN-y) and interleukin 4 (IL-4) production by peripheral blood mononuclear cells (PBMCs) from patients with superficial transitional cell
carcinoma (STCC) of the bladder has been analysed. There were no significant differences in the production of IFN-y and IL-4 by PBMCs
from untreated patients and healthy control subjects after 24 h of phytohaemagglutinin (PHA) stimulation. However, between 3 and 6 months
afterfinishing the prophylactic intracavitary treatment with IFN-a-2b, PHA-stimulated PBMCs from patients with STCC of the bladder showed
a significantly enhanced production of IFN-y and a significantly decreased production of IL-4. Both IFN-y and IL-4 returned to pretreatment
levels 1 year after ending the treatment. In conclusion, prophylactic intravesical instillations of IFN-a-2b in patients with STCC of the bladder
have an immunoregulatory effect on the production of IFN-yand IL-4 by PBMCs.
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Superficial transitional cell carcinoma (STCC) of the bladder is
most often characterized by its high rate of recurrence following
theinitialendoscopic surgicalresection, despite the absence ofany
identifiable remaining tumour (Torti and Lum, 1987). The hetero-
geneous natural history ofSTCC ofthe bladder(Lynch etal, 1991)
after its endoscopic surgical resection provides a powerful ratio-
nale forthe use ofadjuvantintravesical therapy, inorder to prevent
the recurrence and progression of the disease. At present, the
prophylactic use of intravesical chemotherapy in these patients
continues to be of limited effectiveness, as it has failed to reduce
significantly the rate ofdisease progression and long-term tumour
recurrence (Lamm et al, 1992). Prophylactic immunotherapy of
STCC, as exemplified by intravesical instillations with Bacillus
Calmette-Guerin (BCG), has achieved positive results with a
significant improvement in survival, presumably because of its
ability to induce an effective immune response to tumours
(Prescott et al, 1992; Kaempfer et al, 1996). However, the role of
the immunotherapy in good/intermediate-risk superfilcial bladder
cancer remains undefined. Other immunomodulators have also
been investigated as prophylactic adjuvant treatment for STCC of
the bladder (Jurincic et al, 1988; Glashan, 1990). The potential use
of interferon alpha (IFN-a) as adjuvant prophylactic treatment of
STCC of the bladder has also been investigated (Glashan, 1990).
Comparative randomized clinical trials comparing BCG with
IFN-a in the prophylactic treatment of patients with STCC of the
Received 17June 1996
Revised 13January 1997
Accepted 14 January 1997
Correspondence to: M Alvarez-Mon, Departamento de Medicina, Universidad
de Alcalc de Henares, Carretera Madrid-Barcelona, km 33.600, 28871 Alcalc
de Henares, Madrid, Spain
bladder have not been performed. The mode ofaction ofIFN-a in
these patients remains partially defined. A direct effect of IFN-a
on the tumour cells as well as immunomodulatory effects may be
involved (Einat et al, 1985; Molto et al, 1994; Singh et al, 1995). It
has been shown that prophylactic intravesical instillations of
IFN-a in patients with STCC are associated with in vivo immuno-
modulatory effects. Regulatory effects of intravesical instillations
ofIFN-a have been observed in PBMCs from patients with STCC
of the bladder. These effects include an enhancement of NK-cell
activity and a proliferative response to T-lymphocyte mitogens
(Molt6 et al, 1994, 1995).
Cytokines play an important role in the regulation of the func-
tion ofthe different immune cell populations. In this sense, several
cytokines produced by T lymphocytes have stimulatory or
inhibitory effects on the activation and proliferation of NK cells
andcytotoxic T lymphocytes. It appears thatdifferent subsets ofT-
helper lymphocytes have different patterns of cytokine secretion
as defined by the preferential secretion of either IFN-y or IL-4,
called Th1 and Th2 respectively (Seder & Paul, 1994). These
cytokines show different regulatory effects on the activation of T
lymphocytes and NK cells.
In this paper we investigate the effects of prophylactic intra-
cavitary instillations of IFN-ax-2b on the production of IFN-y and
IL-4 by phytohaemagglutinin (PHA)-stimulated PBMCs in
patients with STCC ofthe bladder.
PATIENTS AND METHODS
Patients and treatments
Seventeen patients with histological proven transitional cell carci-
noma ofthe bladder were analysed. The extent oftumour invasion
was classified according to the tumour, node and metastasis
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Table 1 Patient and tumour characteristics
No. of patients 17
No. of men/no. of women 17/0
Mean age ± SE at diagnosis 66.2 ± 4.3
Primary tumour / recurrent tumour 12.5
Solitary tumour/ multiple tumours 11/6
Associated tumour in situ 0
Histological grade
1 0
2 9
3 8
Histological stage
pTA 5
pTl 12
staging system adopted by the International Union Against Cancer
(Table 1). All the tumours were routinely completely resected with
the muscle layer in each case, and random multiple biopsies were
taken. None ofthepatientshadreceived any treatmentduring the 6
months before the study. All the patients were studied before
transurethral resection of the tumour (TUR), during the second
month of a 3-month treatment with weekly intracavitary instilla-
tions of 50 x 106 IU of IFN-a-2b (Intron A, Schering-Plough,
Kenilworth, NJ, USA) and 3, 6 and 12 months after ending treat-
ment. Sixteen age- and sex-matched healthy individuals were also
selected for the study as healthy control subjects. Blood samples
were obtained before the surgical and anaesthetic procedures, and
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informed patient consent for the study was secured. The clinical
evolution of the patients was analysed 1 year after finishing the
prophylactic intravesical IFN-a-2b treatment. After this time,
none ofthefivepatients who werebeingtreatedforarecurrence of
an earlier STCC hadhad a new recurrence, and nine ofthe patients
who had no previous history of the disease had not had a recur-
rence. However, three patients who had had no previous history of
the disease did have a recurrence during this time.
Cell separation
PBMCs were obtained by density-gradient centrifugation (Ficoll-
Hypaque) (Lymphoprep, Nyegaard, Oslo, Norway) and suspended
in RPMI-1640 medium (Whitaker Bioproducts, Walkersville,
MD, USA) containing 10% heat-inactivated fetal bovine serum
(Biochrom, Berlin, Germany), L-glutamine (2 mm, Flow Lab.,
Irvine, UK), Hepes (0.5%, Flow Lab) and 1% penicillin-strepto-
mycin (Difco Lab., Detroit, MI, USA). This will be referred to as
complete medium. Next, cell viability was checked by trypan blue
exclusion. After counting, cells were resuspended in complete
medium.
Cell cultures and measurement of cytokine productions
PBMCs (5 x 106 cells ml-l) were cultured in complete medium on
24-macrowell plates (Costar, Cambridge, MA, USA) with phyto-
haemagglutinin M (PHA) (10 jg ml-1, Difco Lab.) either alone or
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Figure 1 There were no significant differences in the production of IFN-y (A) and IL-4 (B) by PBMCs (5 x 106 cells ml-') from untreated patients with STCC of
the bladder (n = 17) and healthy control subjects (n = 16), after 24 h of PHA-stimulated culture (P> 0.05). Results represent the median and interquartile ranges
of duplicate samples performed in a solid-phase lntertest-y ELISA kit and expressed as pg ml-'. Horizontal bars within boxes show the median; boxes show the
interquartile range from percentile 25 to percentile 75; vertical bars show the 90% confidence interval. O, Control subjects; X, patients
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Figure 2 Production of IFN-yby PHA-stimulated cultures of PBMCs from
patients with STCC before and 3-6 months after finishing intracavitary
IFN-a-2b instillations (n = 8) and from healthy control subjects (n = 10) was
significantly enhanced in the presence of IFN-a-2b in the culture medium
(P< 0.05) (A). However the addition of IFN-a-2b to PHA-cultures of PBMCs
(5 x 106 cells ml-') from the same untreated patients or from patients treated
for 3-6 months with intracavitary IFN-a-2b (n = 8) or from healthy control
subjects (n = 10) does not significantly increase IL-4 production after 24 h of
culture (P> 0.05) (B). The results represent the median (horizontal bars) and
interquartile ranges (from 25% to 75% for boxes and to 90% of confidence
interval for vertical bars) of duplicate samples performed in a solid-phase
Intertest-y ELISA kit and expressed as pg ml-'. *P< 0.05 compared with PHA
alone. El, PHA; X, PHA + IFN-a-2b
in the presence of IFN-a-2b (1000 IU ml-'). Cultures were incu-
bated for 24 h at 37°C in a humid atmosphere containing 5%
carbon dioxide. Supematants were harvested afterincubation, ster-
ilized by filtration through an 0.22-jim filter (Millipore, Bedford,
CA, USA), aliquoted and quickly stored at -40'C until measure-
ment. Concentrations of cytokines were assayed using commer-
cially available IFN-,y (Endogen, Boston, MA, USA) and IL-4
(Genzyme, Cambridge, MA, USA) ELISA kits. The results are
expressed as pg ml-'. The detection limit ofthe IFN-yand IL-4 test
kits are 100 and 45 pg ml-1 respectively.
Staining of cells and flow cytometry analysis
For immunofluorescence staining, PBMCs were incubated with
combinations of fluorescein (FITC, green) and phycoerythrin (PE,
red)-labelled monoclonal antibodies (MAbs). Control studies
involving unstained cells and cells incubated with isotype-matched
irrevelant FITC- and PE-labelled MAbs were performed with each
experiment. The following two- and one-colour MAbs were used to
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Figure 3 IFN-y production by PHA-stimulated cultures of PBMCs from
patients with STCC of the bladder treated with intracavitary IFN-a-2b
instillations (n = 13) was significantly enhanced 3-6 months afterfinishing
the treatment compared with the levels found before treatment (P < 0.05),
and declined thereafter (P> 0.05). However, the production of IL-4 by PHA-
stimulated cultures from patients decreased significantly 3 and 6 months
after finishing the treatment compared with the levels found before and
during treatment (P< 0.05). PBMCs (5 x 106 cells ml-') were cultured in the
presence of the indicated amounts of PHA for 24 h, and then the supernatant
was harvested, filtered and stored at -400C until use. The results represent
the median (horizontal bars within boxes) and interquartile range (from 25%
to 75% for boxes and to 90% of confidence interval for vertical bars) of
duplicate samples performed in a solid-phase lntertest-y ELISA kit and
expressed as pg ml-'. *P< 0.05 compared with pretreatment values. rI,
IFN-y, E,IL-4
identify PBMC populations: leucoGATE (anti-leucocyte FITC/Anti-
Leu-M3 PE) (CD45/CDl4), control (IgG1 FITC/IgG2 PE), Simultest
anti-Leu-4 (FITC) + anti-Leu-llc+19 (PE)(CD3/CD16-56), anti-
Leu-3 (FITC) + anti-Leu-2a (PE)(CD4/CD8) and anti-Leu-12
(FITC)(CD19). All MAbs were obtained from Beckton-Dickinson
(Mountain View, CA, USA). Acquisition andanalysis fortwo-colour
immunofluorescence procedures were carried out with a FACScan
flow cytometer using Lysis II software.
Statistical analysis
To analyse the results, data from the groups were compared with
the unpaired Mann-Whitney U-test. For paired comparisons of
data from the same group, determinations were made using the
Wilcoxon matched-pairs sign test. A P-value ofless than 0.05 was
considered to indicate a significant difference between groups.
Cytokine levels are given as the median and interquartile range.
RESULTS
Significative increase of IFN-yand significative
decrease of IL-4 production by PHA-stimulated PBMCs
from patients with STCC of the bladder after
intravesical prophylactic treatment with IFN-Oa-2b
The first step was to study IFN-y production by PHA-stimulated
PBMCs from patients with STCC ofthe bladder before the begin-
ning of treatment, and from healthy control subjects. There were
British Journal ofCancer (1997) 75(12), 1849-1853
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Table 2 Phenotypical distribution of PBMCs from patients with STCC of the bladder before and after prophylactic treatment with
intracavitary IFN-a-2b instillations (n = 8) and from healthy control subjects (n = 12)
STCC patients
PBMCs Control subjects Before treatment 3 months after treatment
CD3+ 70 (61-77) 70 (63-73) 70 (62-79)
CD16+/56+ 26 (16-33) 28 (23-31) 33 (25-40)
CD19+ 9 (5-13) 10 (6-14) 11 (9-13)
CD4+ 42 (37-46) 34 (31-38) 30 (27-35)a
CD8+ 31 (28-36) 33 (29-37) 38 (33-41)
Ratio CD4/CD8 1.68 (1.5-1.7) 1.19 (0.6-1.3) 0.8 (0.6-1.4)b
Results are expressed as median and interquartile range. ap< 0.05 vs CD4+ of healthy control subjects. bp< 0.05 vs the ratio of
CD4+/CD8+ PBMCs of control subjects.
no statistically significant differences in PBMC production of
IFN-y between the patients with STCC of the bladder and the
healthy control subjects (P > 0.05) (Figure lA).
The effect ofIFN-a-2b in the culture medium on the production
of IFN-y by PHA-stimulated PBMCs from patients and healthy
control subjects was also studied. As shown in Figure 2A, the
production of IFN-y by PHA-stimulated PBMCs from STCC
patients, studied before treatment and 3-6 months after finishing
the 3-month treatment with intracavitary IFN-a-2b instillations,
and from healthy control subjects, was significantly enhanced in
the presence ofIFN-a-2b in the culture medium (P < 0.05).
The effects of prophylactic IFN-a-2b intravesical instillations
on the production ofIFN-yby PHA-stimulated PBMCs in patients
were analysed several times during the first year offollow-up. As
shown in Figure 3, there was no increase in the production ofIFN-
y by PHA-stimulated PBMCs from patients during the second
month of treatment (P > 0.05). The increase in IFN-y production
by PHA-stimulated PBMCs from patients analysed between 3 and
6 months after finishing the treatment, with respect to that found
before initiating the treatment and during the 3 months ofintracav-
itary IFN-a-2b instillations, was significant (P <0.05). There were
no significant differences in IFN-yproduction by PHA-stimulated
PBMCs from patients before the treatment and 1 year after
finishing the intracavitary instillations with IFN-a-2b (P > 0.05).
IL-4 production was studied at the same time and under the
same conditions as IFN-y production. There were no statistically
significant differences in the production of IL-4 by PBMCs
between untreated STCC patients and healthy control subjects
(P > 0.05) (Figure IB).
The effect ofIFN-a-2b on the production ofIL-4 by PHA-stimu-
lated PBMCs from patients with STCC ofthe bladder, before treat-
ment and 3-6 months after finishing the intracavitary IFN-a-2b
instillations andfromhealthy control subjects was examined. Figure
2B, shows that in both healthy control subjects and patients the
exogenous addition of IFN-a-2b to the culture medium of PHA-
stimulated PBMCs did not significantly modify the production of
IL-4 with respect to that achieved in its absence (P > 0.05).
The effects of the prophylactic intravesical instillation of IFN-
a-2b on the production of IL-4 by PHA-stimulated PBMCs from
the patients during a year's follow-up was also studied. As
shown in Figure 3, there were no significant differences in IL-4
production by PHA-stimulated PBMCs from patients measured
during the second month of treatment with intracavitary instilla-
tions of IFN-a-2b, and that found before treatment (P > 0.05).
However, there was a significant decrease in IL-4 production by
PHA-stimulated PBMCs from patients when analysed between
3 and 6 months after finishing the treatment, with respect to
that found before initiating the treatment (P < 0.05). There were
no significant differences between IL-4 production by PHA-
stimulated PBMCs from patients before treatment and that after
1 year of finishing the intracavitary instillations with IFN-a-2b
(P > 0.05) (Figure 3).
IFN-y and IL-4 production by PHA-activated PBMCs was
analysed in six healthy control subjects at the beginning and at the
end of a 6-month period. No significant differences were found in
the cytokine production between these samples (P > 0.05) (data
not shown).
As shown inTable 2, there were no significantdifferences in the
percentages of cells that express the antigens CD3, CD16/56,
CD19, CD4 and CD8 in PBMCs from untreated patients with
STCC ofthe bladder and healthy control subjects. However, 3 and
6 months after finishing the 3-months intracavitary instillations
with IFN-a-2b, the percentage of CD4+ lymphocytes and the
CD4+/CD8+ ratio in PBMCs from STCC patients were signifi-
cantly decreased compared with those found in healthy control
subjects (P < 0.05), but there were no significant differences with
respect to the values found in these patients before their intra-
cavitary treatment (P > 0.05).
DISCUSSION
The cytokines IFN-yand IL-4 play a pivotal role in the regulation
ofthe immune response induced by antigenic stimulation. IFN-,yis
mainly produced by T lymphocytes and NK cells. It is known that
IFN-y regulates the activation of putative anti-tumour effector
cells, including macrophages, NK cells and cytotoxic T lympho-
cytes (Kasahara et al, 1983; Murakata et al, 1985). IFN-yproduc-
tion by PBMCs is frequently impaired in patients with advanced
neoplasms (Ikemoto et al, 1990). IL-4 is mainly produced by T
lymphocytes (Hayakawa et al, 1991). IL-4 is involved in the
modulation of activation and proliferation ofcytotoxic T lympho-
cytes, and there are controversial reports about its effects on NK
cells (Hayakawa etal, 1991; Spits et al, 1988; Higuchi et al, 1989).
There is increasing evidence that different subsets of T lympho-
cytes have different patterns of cytokine secretion, as defined
according to the preferential secretion ofIFN-,yor IL-4, called Th1
and Th2 respectively. It appears that both T-lymphocyte subsets
negatively cross-regulate each other (Heinzel et al, 1989).
Our results show that PBMCs from untreated patients with
STCC ofthe bladder have a normal production ofIFN-yand IL-4.
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Intracavitary prophylactic treatment with IFN-a-2b in these
patients is associated with a significant modification ofthe pattern
of PBMC secretion of these two cytokines. The increased IFN-y
production parallels a decreased IL-4 production by PBMCs from
these patients. This effect is mainly observed 3-6 months after
finishing the intracavitary treatment with IFN-a-2b and has virtu-
ally disappeared after 12 months of follow-up. These modifica-
tions in the pattern ofIFN-y and IL-4 secretion by PBMCs found
in patients with STCC ofthe bladder prophylactically treated with
intracavitary IFN-a-2b instillations suggest that the induction of
a bias towards the preferential use and/or activation of the T-
lymphocyte subset that produces IFN-y in these patients. TheTh,
subset appears to be mainly implicated in the regulation of
immune responses involving cytotoxic T lymphocytes and NK
cells. It seems that the modification in the pattern of cytokine
secretion by PBMCs from STCC patients treated with intracavi-
tary IFN-a-2b, might be involved in the described activation of
NKcells andTlymphocytes found in theperipheral blood ofthese
patients (Molt6 et al, 1994, 1995).
Our findings clearly show that prophylactic intracavitary treat-
mentwith IFN-a-2b inpatients with STCC ofthebladder notonly
has a local effect on the bladder wall, but also has a systemic
immunomodulatory effect on the T-lymphocyte compartment,
with a marked functional consequence on the pattern of
lymphokine secretion. The mechanism by which a locally admin-
istered cytokine can induce an extended systemic effect is as yet
unknown. Perhaps the intravesical instillations of IFN-a induce a
local immune response in the bladder wall that has a delayed
systemic consequence. The systemic effects of intravesical instil-
lations with IFN-a might be explained by the recirculation of
locally activated T lymphocytes and/or as a consequence of the
generalized functional interactions found in the immune system.
According tothe known biological effects ofLFN-a, the mecha-
nisms of action of the intravesical instillations of IFN-a as a
prophylactic anti-tumoral treatment mightbe multiple (Einat et al,
1985; Singh et al, 1995). The potential 'clinical significance of
these findings has to be studied. The analysis ofthe immunoregu-
latory effects ofIFN-a may be a useful tool in the optimization of
this therapeutical modality in the prophylaxis ofthe recurrences of
STCC ofthe bladder. Our data clearly show that the prophylactic
intracavitary treatment ofpatients with STCC of the bladder with
IFN-a-2b has a transient systemic immunomodulatory effect. It
might be possible to suggest that the maintenance of the immune
system activation could improve the clinical results obtained with
prophylactic instillations of IFN-a in patients with STCC of the
bladder. However, analysis ofthe potential clinical significance of
the immunomodulatory effects of the prophylactic intracavitary
instillations of IFN-a-2b in patients with STCC of the bladder
requires further studies.
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